Published in Law and Health Weekly, June 24th, 2006
AR-709 is in the investigational new drug (IND) enabling stage and is expected to enter human clinical trials in 2006.
The in vitro studies, which are being reported, comprised a total of 451 Streptococcus pneumoniae clinical isolates and were conducted by professor Peter Appelbaum at Hershey Medical Center, Pennsylvania and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.